Brouwer K L, Kostenbauder H B, McNamara P J, Blouin R A
J Pharmacol Exp Ther. 1984 Dec;231(3):649-53.
The pharmacokinetics of the enzyme inducer, phenobarbital, was evaluated in genetically obese and lean Zucker and lean Sprague-Dawley rats. The volume of distribution of phenobarbital in obese Zucker rats was larger (0.416 liter) than for lean Zucker (0.299 liter) or Sprague-Dawley rats (0.312 liter). Standardizing the volume of distribution for total body weight in the obese and lean Zucker and lean Sprague-Dawley rats resulted in similar volume terms. Intra- and inter-strain differences in phenobarbital clearance were observed between the obese and lean Zucker (11.9 and 14.1 ml/hr, respectively) and lean Sprague-Dawley rats (23.0 ml/hr). Greater differences in phenobarbital clearance were observed when clearance was corrected for body weight. Whether comparing the absolute or standardized pharmacokinetic data, lean and obese Zucker rats will exhibit 2- to 3-fold higher phenobarbital plasma concentrations after administration of a standard 75- to 100-mg/kg enzyme-inducing regimen relative to Sprague-Dawley rats. Pharmacokinetic parameters from the single dose study were used to calculate appropriate phenobarbital doses (21-58 mg/kg/12 hr) to achieve similar steady-state phenobarbital plasma concentrations after chronic oral administration in all three groups of rats. Steady-state phenobarbital clearance values were not significantly different from clearance values after single dose administration in each group of rats. The dramatic intra- and inter-strain alterations in phenobarbital disposition demonstrated in this study explain the high mortality reported in Zucker rats after administration of traditional enzyme induction doses of phenobarbital. Differences in phenobarbital disposition should be considered in enzyme induction studies.
在遗传性肥胖和瘦型的 Zucker 大鼠以及瘦型的 Sprague-Dawley 大鼠中评估了酶诱导剂苯巴比妥的药代动力学。苯巴比妥在肥胖 Zucker 大鼠中的分布容积更大(0.416 升),高于瘦型 Zucker 大鼠(0.299 升)或 Sprague-Dawley 大鼠(0.312 升)。将肥胖和瘦型 Zucker 大鼠以及瘦型 Sprague-Dawley 大鼠的分布容积按总体重进行标准化后,得到了相似的容积值。在肥胖和瘦型 Zucker 大鼠(分别为 11.9 和 14.1 毫升/小时)与瘦型 Sprague-Dawley 大鼠(23.0 毫升/小时)之间观察到了苯巴比妥清除率的种内和种间差异。当清除率按体重校正时,观察到苯巴比妥清除率的差异更大。无论比较绝对的还是标准化的药代动力学数据,相对于 Sprague-Dawley 大鼠,在给予标准的 75 至 100 毫克/千克酶诱导方案后,瘦型和肥胖 Zucker 大鼠的苯巴比妥血浆浓度将高出 2 至 3 倍。单剂量研究的药代动力学参数用于计算合适的苯巴比妥剂量(21 - 58 毫克/千克/12 小时),以便在三组大鼠长期口服给药后达到相似的苯巴比妥稳态血浆浓度。每组大鼠的苯巴比妥稳态清除率值与单剂量给药后的清除率值无显著差异。本研究中所展示的苯巴比妥处置的显著种内和种间改变解释了在给予传统酶诱导剂量的苯巴比妥后 Zucker 大鼠中报道的高死亡率。在酶诱导研究中应考虑苯巴比妥处置的差异。